Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger, Ian E. Krop, Denise A. Yardley et al.|Cancer Discovery|2021Cited by 241
HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trialZheqi Li, Kornélia Polyák, Otto Metzger et al.|Journal of Clinical Investigation|2024Cited by 29